Catherine Ulman, MD
NPI 1386063642 · Dermatology Physician · Westerville, OH
Enrolled with Medicare as Practitioner - Dermatology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1386063642
- Entity type
- Individual
- Primary specialty
- Dermatology PhysicianAllopathic & Osteopathic Physicians
- Credential
- MD
- Sex
- Female
- Sole proprietor
- No
- License
- 35.133388 (OH)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure28% of score
12 yrs in NPPES registry
- Profile completeness28% of score
100% of core fields populated
- Practice footprint17% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)28% of score
2,464 Medicare services, 2024 (ranked within specialty)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our methodology.
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Destruction of Precancer Skin Growth, 2-14 Growths17003 | 1,010 | $6 |
| Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213 | 414 | $88 |
| Destruction of Precancer Skin Growth, 1 Growth17000 | 312 | $51 |
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 232 | $125 |
| Destruction of Skin Growth, 1-14 Growths17110 | 163 | $106 |
| Biopsy of Related Skin Growth, First Growth |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 19 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Ketoconazole | 221 | 106 |
| Triamcinolone Acetonide | 89 | 60 |
| Doxycycline Monohydrate | 67 | 22 |
| Mupirocin | 66 | 45 |
| Fluocinonide | 54 | 35 |
| Clobetasol Propionate | 43 | 29 |
| Tacrolimus | 40 | 21 |
| Betamethasone/Propylene Glycbrand: Betamethasone Diprop Augmented | 38 |
Practice location
Mailing address
Registry dates
- Enumerated
- 2014-04-15
- Last updated
- 2026-02-25
- Certified
- 2026-02-25
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.